Acasti Pharma (Acasti Pharma) EPS Growth Rate (Future 3Y To 5Y Estimate) : N/A (As of Apr. 30, 2024)

View and export this data going back to 2011. Start your Free Trial

What is Acasti Pharma EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Acasti Pharma's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.

Competitive Comparison of Acasti Pharma's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Biotechnology subindustry, Acasti Pharma's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acasti Pharma's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acasti Pharma's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where Acasti Pharma's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.

Acasti Pharma (NAS:ACST) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Acasti Pharma EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of Acasti Pharma's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.

Acasti Pharma (Acasti Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acasti Pharma Inc (NAS:ACST) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Comparable Companies

Traded in Other Exchanges

A1P0:Germany

Address

3009 Boulevard de la Concorde East, Suite 102, Laval, QC, CAN, H7E 2B5

Website

https://www.acastipharma.com

Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.

Executives

George Kottayil	director	49 OLD BEAR BROOK ROAD, PRINCETON NJ 08540
A Brian Davis	director	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Edward Neugeboren	director	282 NEW NORWALK ROAD, NEW CANAAN CT 06840
Vimal Kavuru	director	11 MAACKA DRIVE, HOLMDEL NJ 07733
Donald Olds	director	545 PROMENADE DU CENTROPOLIS, SUITE 100, LAVAL A8 H7T 0A3
Amresh Kumar	officer: VP Program Management	3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
Carrie D'andrea	officer: VP Clinical Operations	3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
Prashant Kohli	officer: Chief Executive Officer	206 CAMBRIDGE LANE, NEWTOWN PA 13940
R. Loch Macdonald	officer: Chief Medical Officer	200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Michael Derby	director	303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
William A Haseltine	director
Rajitha Grace 2018 Irrevocable Trust	10 percent owner	40 BEY LEA ROAD, SUITE C 202, TOMS RIVER NJ 08753
Swami Sambamurty Iyer	10 percent owner	20 TULSA COURT, MONMOUTH JUNCTION NJ 08852
Brian D. Ford	officer: CHIEF FINANCIAL OFFICER	3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
John Canan	director	C/O REV GROUP, INC., 111 EAST KILBOURN AVENUE, SUITE 2600, MILWAUKEE WI 53202